Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034281 | Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 | PHASE1 | COMPLETED | 16 | — | — | Jun 1, 2002 | Sep 1, 2003 | Feb 2, 2012 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| TAK-165 QD | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TAK-165 | DRUG | Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days. |
Inclusion Criteria: * Have advanced or metastatic cancer which is refractory to standard therapy or subjects for whom there is no known effective therapy. * Have a histologically or cytologically proven diagnosis of a solid tumor known to express HER2. * Have a predicted life expectancy of greater ...